Fig. 1: IL-23 inhibitor suppresses the development of Th17-mediated neutrophilic inflammation in NDA mice.
a Schematic diagram of allergen sensitization and challenge protocol. In the NDA mouse model, sensitization with PBS or OVA + LPS intranasally (i.n.) was followed by challenge with PBS or OVA (i.n.) at the indicated days. Isotype control, αIL-23p19, or dexamethasone (Dex), was treated at 1 hr before every challenge period. The inflammatory response was assessed at 48 hr after the last challenge. b Total cell, neutrophil, and eosinophil counts in BALF measured using flow (n = 8 mice per group). c RORγt+, T-bet+, and GATA3+ Th cell counts in CD4+ T cells (Live,Dump-FOXP3-CD44+CD4+TCRb+) measured using flow cytometry (n = 6 mice per group). d Levels of Th17 (IL-17), Th1 (IFN-γ), and Th2 (IL-13) cell-related cytokine in BALF (n = 8 mice per group). e Representative H&E staining of lung sections obtained from the indicated conditions. Scale bar = 100 μm. f Inflammatory scores quantified from H&E staining (PBS/PBS (n = 3), OVA + LPS/PBS (n = 3), OVA + LPS/OVA (n = 3), OVA + LPS/OVA + αIL-23p19 (n = 5), and OVA + LPS/OVA+Dex (n = 5)). g Representative PAS staining of lung sections obtained from the indicated conditions. Scale bar = 200 μm. h PAS-positive area quantified from PAS staining (n = 4 mice per group) (i)Penh values measured using whole body plethysmography (PBS/PBS (n = 8), OVA + LPS/PBS (n = 9), OVA + LPS/OVA (n = 8), OVA + LPS/OVA + αIL-23p19 (n = 5), and OVA + LPS/OVA+Dex (n = 8)). j Rrs values measured using an invasive ventilated lung resistance method (PBS/PBS (n = 3), OVA + LPS/PBS (n = 4), OVA + LPS/OVA (n = 5), OVA + LPS/OVA + αIL-23p19 (n = 4), and OVA + LPS/OVA + Dex (n = 5)). Data are shown as mean ± s.e.m. Significance was determined by one-way analysis of variance (ANOVA) with Tukey’s post hoc correction (b–d, f, h) and two-way ANOVA with Sidak’s post hoc correction (i, j).
